Outlook Therapeutics Announces $55M Registered Offering of Stock and Warrants

What Happened
Outlook Therapeutics, Inc. announced on August 12, 2026 that it entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC for a registered public offering of 55,555,556 shares of common stock and accompanying warrants, priced together at $0.99 per share + warrant. The offering was scheduled to close on or about August 14, 2026, and the company estimated gross proceeds of approximately $55.0 million (before fees and expenses), assuming no warrant exercises. The underwriters had a 30‑day option to purchase up to 8,333,333 additional shares and/or warrants; the underwriters exercised that option with respect to the Warrants.

Key Details

• Offering size: 55,555,556 common shares and accompanying warrants; public unit price $0.99.
• Estimated gross proceeds: approximately $55.0 million (before underwriting discounts/commissions and expenses), assuming no warrant exercises.
• Over-allotment: up to 8,333,333 additional shares and/or warrants (underwriters exercised option for the additional warrants).
• Warrant terms: each warrant exercisable immediately, expires five years from issuance, initial exercise price $1.10 per share (subject to customary adjustments).
• Exercise limit: holders cannot exercise into a position that would exceed 4.99%, 9.99% or 19.99% ownership (holder can elect a lower/higher percentage up to 19.99% with 61 days’ notice).
• Insider participation: GMS Ventures & Investments (largest stockholder) purchased 2,525,252 units; CEO Robert Jahr bought 151,515 units; CFO Lawrence Kenyon bought 101,010 units.
• Offering made under the company’s effective Form S-3 registration (No. 333-278340); underwriting agreement and warrant form are filed as exhibits.

Why It Matters
This transaction is intended to raise immediate capital for Outlook Therapeutics. For investors, the offering dilutes existing shareholders because new shares are being issued and the accompanying warrants can increase the share count if exercised. The warrants’ $1.10 exercise price is above the $0.99 unit sale price, meaning warrants are initially out‑of‑the‑money until the stock trades above $1.10. Insider purchases signal participation by major shareholders and management, but completion of the offering remains subject to customary closing conditions disclosed in the filing.